# Roche Pharmaceuticals and Transforming Healthcare in Asia Pacific with Ahmed Elhusseiny

- **Show:** Analyse Asia with Bernard Leong
- **Published:** 29 Nov 2022
- **Source:** https://podcasters.spotify.com/pod/show/analyseasia/episodes/Roche-Pharmaceuticals-and-Transforming-Healthcare-in-Asia-Pacific-with-Ahmed-Elhusseiny-e39jkmg
- **Transcript:** https://podcasts.opennash.com/shows/analyse-asia/roche-pharmaceuticals-and-transforming-healthcare-in-asia-pacific-with-ahmed-elh-302c7b/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

Ahmed Elhusseiny of Roche argues that the pandemic taught healthcare in Asia Pacific that it must shift from treating illness after it appears to preventing it, with personalised care built on data and digital tools. He says the tools already exist, and the real challenge is putting them into practice through partnerships.

The episode moves from the pandemic's damage, such as disrupted care and backlogs, to its upside: faster regulation, telehealth and data use. The tension is that crisis-driven partnerships were easy to form because the need was urgent, whereas ageing-population challenges need long-term commitment and clear alignment among partners..

## Key insights

1. **The pandemic disrupted care far beyond COVID** Elhusseiny says diabetes and cancer care pathways were disrupted, creating patient backlogs, missed diagnoses and interrupted therapies. This showed the limits of existing healthcare systems.
2. **Crisis sped up regulation and digital health** He says regulatory approval pathways were accelerated and telehealth went from pilot to widespread use. Data was also used at scale to track the pandemic.
3. **Pandemic tools are being reused for other health needs** Malaysia's MySejahtera tracing app is being repurposed to hold health records, including vaccinations and blood glucose levels. Telemedicine tech is now used for telementoring healthcare professionals.
4. **Personalised care uses individual traits, not one regimen** Treatment would be tailored using genetics, gender and age instead of an identical pill schedule for everyone. He argues this improves outcomes, reduces waste and can lower costs when done at scale with data.
5. **Ageing populations need long-term partnerships** He calls the ageing population a slowly creeping epidemic bringing Alzheimer's and cardiovascular disease. Unlike the acute pandemic, tackling it needs sustained commitment and clear alignment on outcomes.

## Questions this episode answers

### What does personalised healthcare mean?

Ahmed Elhusseiny describes it as tailoring care to each person's characteristics, such as genetics, gender and age, instead of giving everyone the same regimen. The aim is the right care at the right time.

### How did the pandemic change healthcare in Asia Pacific?

It disrupted care for conditions like diabetes and cancer, but it also sped up regulatory approvals, telehealth and large-scale use of data. Elhusseiny sees the second part as a basis for future innovation.

### How would we know if personalised healthcare is working?

Elhusseiny says success would show in longer and better-quality lives, less disability, and fewer and shorter hospital stays. It would also make the healthcare system more efficient.

### What is Roche doing in Asia Pacific?

Elhusseiny says Roche, a 125-year-old Swiss company, has manufacturing, research and development, commercial and medical services across the region. His own role focuses on widening patient access to therapies.

### Why does he say partnerships are hard but necessary?

He says challenges like an ageing population are too big for any one party. The difficulties are aligning on outcomes and sustaining long-term commitment, which the acute COVID crisis did not require.

## Facts

- **Ahmed Elhusseiny** [0:05:23]: "This is a 125-year-old company. It's a Swiss company, but it's truly a global company with a global footprint, including, of course, in Asia Pacific."
- **Ahmed Elhusseiny** [0:05:23]: "Our mission is around doing now what patients need next."
- **Ahmed Elhusseiny** [0:05:55]: "Our motto is first in class, best in class."
- **Ahmed Elhusseiny** [0:06:27]: "Roche, broadly speaking, is also Roche Pharmaceuticals and Roche Diagnostics."
- **Ahmed Elhusseiny** [0:06:27]: "our presence extends from manufacturing to research and development and, of course, commercialization and medical services to patients all over the region."
- **Ahmed Elhusseiny** [0:02:36]: "I did a PhD in neuroscience."
- **Ahmed Elhusseiny** [0:02:36]: "I'm originally from Egypt, but I'm also Canadian."
- **Ahmed Elhusseiny** [0:09:42]: "it had also broader impact on the healthcare system as a whole. And this really impacted almost every care pathway that exists."
- **Ahmed Elhusseiny** [0:10:37]: "even things like regulatory approval and the pathways by which products get reviewed. Those were absolutely accelerated because of COVID"
- **Ahmed Elhusseiny** [0:11:51]: "If you lived in Malaysia or in Singapore, of course, you had the track and trace apps."
- **Ahmed Elhusseiny** [0:11:51]: "in Korea, they were also using other data sources to be able to track the pandemic. So buying patterns, for example."
- **Ahmed Elhusseiny** [0:13:04]: "One example is a partnership we did with the WHO to allocate one of our products and to make sure that the allocation of this product is as fair and just as possible."
- **Ahmed Elhusseiny** [0:13:41]: "in Thailand, we partnered with local associations there to really be able to provide COVID testing in remote areas using tuk-tuks."
- **Ahmed Elhusseiny** [0:17:49]: "the track and trace app in Malaysia, which is called MySejHarta, it was initially, of course, developed to be able to to track, but now is being repurposed"
- **Ahmed Elhusseiny** [0:17:49]: "including vaccination records and also blood glucose levels, which of course then can have potential"
- **Ahmed Elhusseiny** [0:17:49]: "Those technologies are now being repurposed for things like telementoring and building skills and capabilities for healthcare professionals around Asia."
- **Ahmed Elhusseiny** [0:15:29]: "In the APAC region, the aging population is a slowly creeping pandemic or epidemic."
- **Ahmed Elhusseiny** [0:22:46]: "based on your genetic profile, based on your background, your healthcare, you would get something different based on that than I would."
- **Ahmed Elhusseiny** [0:24:21]: "Personalized healthcare brings together medical science, digital technology, and data science."
- **Ahmed Elhusseiny** [0:24:49]: "we could see people staying shorter periods in hospitals. So hospitalization rates would go down."
- **Ahmed Elhusseiny** [0:26:43]: "I'm actually reading a book called In the Dragon's Shadow, which actually is very topical for the region I'm in right now."

## Transcript

**[0:00:02] Speaker 3:** Analyse Asia is brought to you by S.O .V.L. Do you manage your own IT for distributed teams across Asia Pacific? Then you know how painful that can be. S.O .V.L. helps your in-house team by taking cumbersome tasks off their hands and giving them the tools to manage IT effectively. Get help across Asia Pacific from onboarding, procuring devices, to real-time IT support and off-boarding. With our state-of-the-art platform, gain full control of all your IT infrastructure in one place.

**[0:00:34] Speaker 3:** Our team of IT support pros are keen to help you grow. Check out esevel.com and get a demo today. Use our referral code ASIA for 10 % off. Terms and conditions apply.

**[0:00:53] Ahmed Elhusseiny:** Because of the pandemic, we all became patients. We all became aware of diagnostic tools, therapeutic interventions. The level of awareness that exists now around this specific topic is very high, but it also translates into us being more aware about why it's important to be preventative. A mask is preventative. Exercise in the post-pandemic world is preventative for heart conditions. And I think there's a much larger appetite now to start looking at how we can work together in partnership to identify those things that allow us to intervene early in order to prevent or to slow down any types of conditions that could happen to individuals, shift the narrative around how we approach healthcare in Asia.

**[0:01:38] Ahmed Elhusseiny:** And I think this is absolutely necessary because of the challenges that we face, and it will be totally enabled by data and the technology. And so the tools for that exist. The biggest question really is how we start to implement them.

**[0:01:57] Bernard Leong:** Welcome to Analyse Asia, the premier podcast dedicated to dissecting the pulse of business technology and media in Asia. I'm Bernard Leong, and the post-COVID-19 world is where the transformation of healthcare in Asia-Pacific will be instrumental before the next one. With me today, Ahmed Elhusseiny, Area Head in Asia-Pacific, Roche Pharmaceuticals, to tell us how we need to transform healthcare in the Asia-Pacific. Ahmed, welcome to the show. Thank you, Bernard.

**[0:02:26] Ahmed Elhusseiny:** I'm looking forward to a great conversation.

**[0:02:29] Bernard Leong:** And it's your first time on the show. So we actually want you to dive into your origin story. How did you start your career?

**[0:02:36] Ahmed Elhusseiny:** Okay, let me begin by saying I'm originally from Egypt, but I'm also Canadian. And I lived in both countries. And I started my career after my PhD. I did a PhD in neuroscience. And up to that point, I was actually quite single-mindedly tracked, thinking that I'm going to become a professor or a researcher. And then opportunities came across and I had an opportunity to transition into a biotech company to do clinical research. So I entered into the pharmaceutical industry of the biotech or healthcare industry through the research, clinical research regulatory path, and then transitioned to more on to the business side and having stints in business development, marketing, global marketing, sales, and then also did some global strategic work

**[0:03:24] Ahmed Elhusseiny:** in the headquarters before moving on to my role here

**[0:03:27] Bernard Leong:** in Singapore, in APAC as the area head. And of course, coming from an academic background, I think you and I share very interesting backgrounds as academics previously, and then you transitioned into going into business in the healthcare sector. I would like to know what are the most interesting career lessons which you can share with my audience? Well, that's obviously a

**[0:03:49] Ahmed Elhusseiny:** great question and one that I think we could spend a lot of time on. I will say that looking back now and just appreciating it, looking at your career as a learning journey rather than I need to get here for that reason or this reason, really looking at it from a perspective of kind of what can I learn and what can I take out of this and just kind of letting that be the driving force is probably for me a really important career advice or learning for me.

**[0:04:17] Ahmed Elhusseiny:** The second thing I would say is as you're doing that, two things are come out to me as very important as you're making the decisions. What are you really passionate about and can you make a difference? And as you're kind of making choices, again, the titles are important. All of these things are important, but are you really passionate about the work and can you make a difference? Those are important questions to ask yourself as you're making career choices and taking on opportunities.

**[0:04:45] Ahmed Elhusseiny:** So I would say those are probably the two. Again, there's probably a lot more, but let's stick with those two for now.

**[0:04:51] Bernard Leong:** Which comes to the main subject of the day, which I want to talk about Roche and also thinking about how we can transform healthcare in the Asia-Pacific. So as an introduction, can you talk about the vision and mission of Roche globally, maybe specifically for the Roche pharmaceuticals and what it is currently doing in the Asia-Pacific. I mean, many years ago, I was involved in the Human Genome Project as a research scientist, so I'm familiar with what Roche is doing, but it'd be good to give my audience a little bit of background.

**[0:05:21] Bernard Leong:** Yeah, great. I'm happy to do that.

**[0:05:23] Ahmed Elhusseiny:** I think one of the things I should just begin before I just start talking about the mission and vision, just to give a bit of history. This is a 125-year-old company. It's a Swiss company, but it's truly a global company with a global footprint, including, of course, in Asia Pacific. Our mission is around doing now what patients need next. So our company is always thinking about the future, the future of healthcare and how we can help patients today, but more importantly, how can we can plan to help or help patients for the future as well.

**[0:05:55] Ahmed Elhusseiny:** And so a large part of what we do, and anyone who works in this industry knows this, a long-term development and making sure that we have an understanding of the networks and the areas and the stakeholders and the communities that we wanted to impact is really, really important. We're an innovation-driven company. Our motto is first in class, best in class. We want to be always on the cutting edge of science. In addition to being passionate about serving patients, we are also passionate about following the science.

**[0:06:27] Ahmed Elhusseiny:** And on many occasions, this has meant that we don't necessarily, we change paths because the science changes. We follow it all the way until the end and use it as a tool to help and to lead us really to better therapies for patients. We have a strong presence in Asia and Roche, broadly speaking, is also Roche Pharmaceuticals and Roche Diagnostics. And we have a strong presence in Asia. And our presence extends from manufacturing to research and development and, of course, commercialization and medical services to patients all over the region.

**[0:07:02] Ahmed Elhusseiny:** And in addition to that, we also have a lot of our talent in our organization from Asia. And many of them are in Asia, but many of them are also serving in other countries all around the world. So something that we're also very proud of is that we're truly an international company with many opportunities for people to transverse and be able to work across the world.

**[0:07:23] Bernard Leong:** So what is your current role and coverage in Roche Pharmaceuticals as the area head of Asia Pacific?

**[0:07:30] Ahmed Elhusseiny:** So my current role is the Asia-Pacific region. And a large part of my role is to really work with the different ecosystems and work with our people in those environments to help enable access to our therapies to as many patients as possible. And we do this through many different means, whether it's in terms of education, in terms of awareness programs, in terms of working with governments, in terms of partnerships. The intent really is to be, we feel we have incredibly life-saving products in many cases, but they're not saving lives if patients can't access them.

**[0:08:09] Ahmed Elhusseiny:** So a large part of what we do is kind of work with whoever's interested, whoever are the key stakeholders to be able to enable that. And then once that happens, also managing and maintaining the care of patients on those therapies. We look at this as more of a solution for patients than specific products because we really like to look at the entire patient journey and see how we can help patients at almost every single stage in terms of that journey in order to enable them to get the best possible outcome.

**[0:08:42] Bernard Leong:** So I think if we look back, we went through the global COVID-19 pandemic for the past two and a half years, and now we're in a post-pandemic world. I think the way I want to move our conversation forward is just to understand what were the key challenges for the healthcare industry during that period when the pandemic started till now?

**[0:09:02] Ahmed Elhusseiny:** Yeah, the pandemic obviously had a devastating effect. I don't think I need to tell anyone that. And it had a devastating effect on healthcare systems around the world. It was also a wake-up call for healthcare systems with the huge gaps that exist and the inefficiencies that exist in our healthcare systems. COVID obviously put intense pressure on many of our services, and we saw that impact around Asia, we saw it around the world. And certainly, whether it's resources or people, it was a very intense period and one where I think we quickly realized the limitations of the care pathways that we have.

**[0:09:42] Ahmed Elhusseiny:** I should also say that in addition to the impact it had on patients with COVID, it had also broader impact on the healthcare system as a whole. And this really impacted almost every care pathway that exists. So whether you're a diabetic or a cancer patient, these care pathways were completely disrupted as a result of COVID, creating huge backlogs of patients, many missed diagnoses, undertreatments or interrupted therapies. So it had obviously a very devastating impact and really unfortunate for many people.

**[0:10:17] Bernard Leong:** I think it was also a good accelerator to put a lot of technologies at work and systems as well. One question I wanted to get a sense of is how will new systems and maybe innovative healthcare solutions are implemented such that they can address the needs of the patients during the COVID-19 pandemic?

**[0:10:37] Ahmed Elhusseiny:** So I spent quite a bit of time sharing the downside, but there was a flip side to this. And I think you're absolutely right. This acute crisis really forced a change in the way we administer and manage many elements of care. And it did create major changes, even things like regulatory approval and the pathways by which products get reviewed. Those were absolutely accelerated because of COVID and showed us that it is possible to do that. But definitely the area where there was the biggest and most impactful change is on the digital revolution that occurred as a result of the pandemic.

**[0:11:14] Ahmed Elhusseiny:** And really, this extends from most basic things such as telehealth, which I think many of us experienced and we're probably still experiencing now, and opportunities for us to now to be able to receive care in our homes virtually. So this is something that really was maybe a pilot before, but now has become much more widespread and exists today. To the utilization of data pools to track and to trace the pandemic. So this is things that we had maybe experimented with before, but never really done at scale.

**[0:11:51] Ahmed Elhusseiny:** And some of these tools took on a level of sophistication. If you lived in Malaysia or in Singapore, of course, you had the track and trace apps. But for example, in Korea, they were also using other data sources to be able to track the pandemic. So buying patterns, for example. It became very interesting how we could leverage data to be able to use it to be able to drive impact in terms of patient care. So this revolution was certainly an acceleration of many pilots and examples and a hotbed of innovation that occurred as a result of the pandemic.

**[0:12:24] Ahmed Elhusseiny:** And that's the flip side of the pandemic and its impact on healthcare.

**[0:12:28] Bernard Leong:** And given the challenges that you mentioned during the pandemic and given that it's very, very difficult for any healthcare organization to do it alone, whether you're a commercial or whether you're even a government healthcare subsidiary, how did Roche manage to work with partners in the ecosystems to overcome the issues? Because I think one of the key things that you mentioned earlier is that about like distribution, right? You may have the solution, but you still need to find a way to deliver it out to the actual people who need that healthcare service or that healthcare need.

**[0:13:01] Bernard Leong:** Again, the acuteness of this, of the pandemic

**[0:13:04] Ahmed Elhusseiny:** and the acute need for solutions really drove a lot of partnerships. And for Roche, this was broad-based, large partnerships. So for example, Roche, of course, we had both therapies and diagnostic tools that helped with the management of care of COVID. And we would form partnerships with many associations. One example, in order to make sure that this care is applied as widely as possible. One example is a partnership we did with the WHO to allocate one of our products and to make sure that the allocation of this product is as fair and just as possible.

**[0:13:41] Ahmed Elhusseiny:** But other things that we did were maybe even more community-based. So for example, in Thailand, we partnered with local associations there to really be able to provide COVID testing in remote areas using tuk-tuks. So we'd be able to provide the care closer to the people who need it. So there was a wide range of partnerships that came out of this and allowed us to really engage with many of the key players and stakeholders in the healthcare system in a way that we would have never thought to do so in the past before the pandemic.

**[0:14:18] Ahmed Elhusseiny:** But it opens a path for the future in terms of collaborations as well. And this is what I think really excites me is even though there was a specific need that kind of drove it at the stage of the pandemic, there's no need to believe that that's a unique point in time. And there may be many other opportunities and there already are opportunities to build on these partnerships for a wider set of achievements beyond COVID.

**[0:14:43] Bernard Leong:** And that's what I think is really, really exciting. And I think you alluded to the fact that it has actually allowed you to test speed and try to make certain implementation in a difficult environment And of course, now we're in a post-pandemic era. I want to sort of reflect and look, looking backwards a little bit. What are the interesting lessons that you have drawn from implementing these digital technologies, accelerated out of the need of the pandemic?

**[0:15:12] Bernard Leong:** And then after that, mapping it back to now a very, very different world where everybody's returning to the office and maybe thinking about when the next crisis is going to strike, Like, are we going to use these technologies to be able to help us to tie over potentially the next healthcare crisis itself?

**[0:15:29] Ahmed Elhusseiny:** There's obviously a lot of lessons that are translatable. And I would say that the translation doesn't need to wait until the next pandemic. We have other challenges in our healthcare system that we need to face. In the APAC region, the aging population is a slowly creeping pandemic or epidemic. and it comes with a whole series of issues and diseases such as Alzheimer's, for example, and cardiovascular disease, we need to start today to start to tackle those challenges.

**[0:15:59] Ahmed Elhusseiny:** And we should take the learnings that we have had from the pandemic and translate them to the future of those challenges. So I would say that that's a really important lesson that came out of this, is that it is possible that we should be open to these types of collaborations because these challenges are too big to be dealt with alone. No one party can deal with it alone. Different parts of the organization brings different skill sets.

**[0:16:25] Ahmed Elhusseiny:** The challenge with these types of partnerships is part of this is the alignment. And I think it's very important to have clear alignment in terms of what outcomes need to be achieved. And the other challenge with them is that a large time, these challenges tend to be long term challenges. And they do require significant long term commitment from the different parties. This is something that's maybe with COVID, with the acute need of COVID, we didn't have to deal with.

**[0:16:54] Ahmed Elhusseiny:** But when you deal with something like an aging population and the upcoming potential for all the types of diseases that come with it, we really need to be able to have much more long term plans, similar approaches, but much more long term plans and much more long term partnerships that allow us to really take stepwise approaches in dealing with those in the appropriate way.

**[0:17:14] Bernard Leong:** We've talked a lot about the ways we think about how to implement technologies into the healthcare system, given the challenges that came from the pre-then pandemic and now post-pandemic. I want to sort of get into, really dive into the weeds. Can you share examples or case studies of the digital technologies that were implemented for the COVID-19 pandemic and now being even repurposed for other users as well? Yes, there's obviously teleconsultation, telemedicine

**[0:17:49] Ahmed Elhusseiny:** approaches. That was clearly something that came out and got used everywhere in the pandemic. Those technologies are now being repurposed for things like telementoring and building skills and capabilities for healthcare professionals around Asia. So using the same type of technologies that we were used for, for example, for consultation, using that to help build capacity and capability. Another example, and I talked about the tracing apps, for example, the track and trace app in Malaysia, which is called MySejHarta, it was initially, of course, developed to be able to to track, but now is being repurposed to be able to record health records of individuals within the country, including vaccination records and also blood glucose levels, which of course then can have potential

**[0:18:37] Ahmed Elhusseiny:** implications for management of diabetes care. So there's examples of these technologies that initially were built for one thing, but then of course, now that we have them, why not use them more broadly or for something else that is a challenge for today? And that's also very exciting when we're able to do that because that's how innovation occurs and how we're able to make these big differences on many of these challenges that we face today.

**[0:19:05] Bernard Leong:** Given the lessons learned from the pandemic, we're now shifting to a post-pandemic world. I guess, what is the rethinking that we need for the healthcare system in the Asia-Pacific region? I think part of the lesson that I think I gather from our conversation is that there's a lot of data collection and there is a better coordination of healthcare needs and delivery of healthcare. So going from there, what is the rethinking that we need?

**[0:19:32] Ahmed Elhusseiny:** One of the things that's come out of the pandemic is having to really re-examine the future of healthcare within Asia Pacific, and particularly with a lens of how we can today install the right components that allow us to lead into a personalized future, personalized healthcare future, and one that allows us to approach preventative care. Because of the pandemic, we all became patients, we all became aware of diagnostic tools, therapeutic interventions. The level of awareness that exists now around this specific topic is very high, but it's also translatable.

**[0:20:15] Ahmed Elhusseiny:** And it also translates into us being more aware about why it's important to be preventative. A mask is preventative. Exercise in the post-pandemic world is preventative for heart conditions. So these things are truly translatable. And I think there's a much larger appetite now to start looking at how we can work together in partnership to identify those things that allow us to intervene now and intervene early in order to prevent or to slow down any types of conditions that could happen to individuals and therefore really shift the narrative around how we approach healthcare in Asia.

**[0:20:53] Ahmed Elhusseiny:** And I think this is absolutely necessary because of the challenges that we face, and it will be totally enabled by data and technology. So the tools for that exist. The biggest question really is how we start to implement them. And this is, I think, the part where partnership is very important, long-term planning and strategizing is very important, but it really is around how we can install these tools and be able to leverage them to be able to create the kind of environment that allows us to move to a world where preventative care is the norm, that patients or people actually have personalized healthcare plans that allow them to take steps today to prevent future or offset future conditions or

**[0:21:42] Ahmed Elhusseiny:** future situations where they wouldn't want to be in. So this is really the vision. And I think one of the important learnings that we got as a result of the pandemic. I want to double click a little bit here.

**[0:21:54] Bernard Leong:** Can you define how data and personalized healthcare can be enabled for the Asia Pacific region to enable the better delivery of the healthcare service itself to the patients?

**[0:22:07] Ahmed Elhusseiny:** When we talk about personalized healthcare, we're really talking about this idea that we approach each individual based on their characteristics, whether it's genomic or gender, age, all these things. And we take all of those things into consideration in the administration of their therapies or their treatments or any elements of their healthcare management. And the idea here is that you really are very strategic in terms of your approaches so that basically you apply the care that's absolutely needed and the right one at the right time for the individual.

**[0:22:46] Ahmed Elhusseiny:** Why that's great? It allows you, of course, to get the highest chance of success and it also prevents you from getting misdiagnosed or mistreated. So in the past, if you or I were to get sick, even today, if we go sick, most likely we'd be given a regimen that is identical. You take a pill in the morning, you take a pill in the evening, you take it for the seven days. In the future, based on your genetic profile, based on your background, your healthcare, you would get something different based on that than I would.

**[0:23:17] Ahmed Elhusseiny:** And it'd be personalized and give me the highest chance of success. Now, why this is really exciting, of course, it helps with definitely driving better patient outcomes. It reduces waste. But the part that's really exciting is that it can be done at scale through data. And this is where it becomes really interesting is that if we're able to aggregate all of this data and use it strategically, we would be able to administer this type of care in a way that would allow us to have much more efficient and effective healthcare system at a lower cost, which I think is very important for everyone involved.

**[0:23:56] Ahmed Elhusseiny:** So I think this is definitely a path that we can take that will allow us to overcome some of the challenges I talked earlier about in Asia. It's a path that will allow us to really overcome these challenges and be very strategic about it. And it is an incredibly powerful concept. its implementation is really the challenge.

**[0:24:16] Bernard Leong:** Then how do we measure the effectiveness of personalized healthcare then?

**[0:24:21] Ahmed Elhusseiny:** Personalized healthcare brings together medical science, digital technology, and data science. And it really, as I said earlier, puts the patient at the center and enables the treatment and the care to be tailored to the individual and create unpersended opportunities for patients. As we shift from these kind of one-size-fits-all approaches to really providing the best possible care for each individual patient, we would be able to measure that by seeing improved both the quantity and the quality of the life of the patients.

**[0:24:49] Ahmed Elhusseiny:** We reduce the impact of disability and ill health on individuals and their families. And importantly, and I talked about this earlier, we bring in efficiencies into the healthcare system, which then allow us to advance better healthcare. So this is how we would be able to measure it. And as a result, we could see people staying shorter periods in hospitals. So hospitalization rates would go down. And obviously this would also reduce the overall burden of care for patients.

**[0:25:20] Bernard Leong:** I only have one final question. What does GREAT look like for Roche Pharmaceuticals in Asia

**[0:25:26] Ahmed Elhusseiny:** Pacific for the next few years? So at the heart of what we do, obviously we want to do what's best for patients. And despite incredible advances that have happened, there's still a huge unmet need in terms of the provision of care all across Asia. So rapid, broad and sustainable access to all kinds of therapies and healthcare solutions is really what GRADE looks like to me. And it's really what I'm very much committed to in my role in APAC.

**[0:25:59] Ahmed Elhusseiny:** I see that there is incredible potential in this region. And I see that at the same time, there's also a huge need. And I think it's all our role to do what we can to make that difference. So if you're asking me, that's what I would love to see.

**[0:26:15] Bernard Leong:** And Ahmed, many thanks for coming on the show. And I would thank you and the many other healthcare providers, whether it's governmental, commercial, who have actually been contributing towards all of our wellbeing during this COVID-19 pandemic and moving beyond. and look forward to speak to you again in the future relating to how healthcare is going to be transformed in the Asia-Pacific. But in closing, I have two very quick questions to ask. Any recommendations that have inspired you recently?

**[0:26:43] Ahmed Elhusseiny:** So I'm actually reading a book called In the Dragon's Shadow, which actually is very topical for the region I'm in right now. And it talks about the interplay between China and the Asia-Pacific region. So I found that book very insightful and inspiring in some ways and interesting. And it's also helped me put in context some of the things that I see on a daily basis. So I would recommend that to anyone who's moving into the region.

**[0:27:09] Bernard Leong:** I'm going to get my amazon.sj and click on the get it book. How do my audience find you? I suppose the easiest way

**[0:27:16] Ahmed Elhusseiny:** is you can reach me on LinkedIn. I do often post and share my thoughts on trends and ideas that I've had. And yeah, that would probably be the best way.

**[0:27:26] Bernard Leong:** And you can totally find us in any podcast platforms and of course, subscribe to us on Analyse Asia, A-N -A-L -Y-S -E on Twitter, or give us a five-star rating on Apple Podcasts or any other podcast platforms that you are on, whether it's Spotify, Castbox, etc. I mean, once again, many thanks for coming on the show and thank you for helping me to understand a little bit on how healthcare is being transformed across the region and I look forward to speaking to you soon.

**[0:27:49] Bernard Leong:** Thank you so much. Thank you.
